Purpose {#sec1}
=======

Intracavitary brachytherapy (ICBT) is important part of definitive radiotherapy protocol of cervical cancer patients. Late adverse events of rectum and bladder are issues of major concern in ICBT \[[@cit0001], [@cit0002], [@cit0003], [@cit0004], [@cit0005], [@cit0006], [@cit0007]\]. Feasibility to conform dose to the target in image based brachytherapy allowed clinicians to adapt dose distribution in organs at risk and tumor in each fraction. Centers practicing image based brachytherapy showed improved dose distribution and outcome, and decreased morbidity. In cervical cancer patients, the cumulative overall and ≥ 2 grade rectal toxicity has been recorded in 12-19% of patients \[[@cit0005], [@cit0006], [@cit0007], [@cit0008], [@cit0009]\].

From basic radiation protection principles, it is well known that increasing the distance is a simple and effective way to reduce radiation exposure. The interest in recent years to physically separate the rectum from the prostate and thereby reduce the rectal radiation dose has been significant. Injection of human collagen into the space between prostate and rectum in prostate cancer patients have shown decline of rectal dose by 25-50% \[[@cit0010], [@cit0011]\]. Till date, there is only a single published case report of this new technique for patients with cervical cancer undergoing external beam radiotherapy (EBRT). Nevertheless, Marnitz *et al*. in their study did not discuss the dosimetric impact of this intervention \[[@cit0012]\]. The present study was initiated to prove the feasibility of hydrogel application in ICBT of cervical cancer in order to reduce rectal toxicity. To the best of our knowledge, the present study is the first report of rectal hydrogel application in ICBT of cervical cancer.

Material and methods {#sec2}
====================

A 56 years old multiparous woman was presented with cervical cancer FIGO (International Federation of Gynecology and Obstetrics) stage IIB. After an magnetic resonance imaging (MRI) confirmed her staging, she was treated with EBRT to a dose of 50.4 Gy in 28 fractions (1.8 Gy/fraction) over 5 weeks along with weekly concurrent injections of cisplatin 40 mg/m^2^. Post EBRT gynecological and imaging assessment showed no residual tumor. She was therefore planned for ICBT. Initially, we planned to deliver a dose of 7 Gy × 3 fractions, one fraction per week. According to our institutional protocol, the patient was admitted one day prior to ICBT application for bowel preparation (digestive enzymes, bisacodyl tablets, and enema). Intracavitary brachytherapy application was done under spinal anesthesia with standard Fletcher-Suit-Delclos (FSD) applicators on 03/09/2014. Computed tomography (CT) of pelvis was done followed by contouring of organs at risk (OAR) (i.e. urinary bladder, rectum, and sigmoid colon), gross tumor volume at brachytherapy (GTVB), high risk clinical target volume (HR-CTV), and intermediate risk clinical target volume (IR-CTV) \[[@cit0013], [@cit0014], [@cit0015]\] using the high-dose-rate (HDR) plus v2.6 treatment planning system (Eckert & Zieglar, Bebig GmBH, Germany). Due to close proximity of the rectum with the target volume, in spite of optimization, we were able to prescribe only 5 Gy to point A (with doses to HR-CTV D~90~ 5.94 Gy, IR-CTV D~90~ 4.54 Gy, rectum D~2cc~ 5.72 Gy, bladder D~2cc~ 5.52 Gy, and sigmoid colon 5.82 Gy; Plan 1). On reviewing the insertion, internal anatomy, and planning, we found out that the key problem for the high rectal and sigmoid doses was the wall separation between the rectum and the cervix, which was very narrow (average = 0.18 cm) ([Figure 1](#f0001){ref-type="fig"}). Treatment was delivered through ^60^Co HDR brachytherapy unit (Multisource, Eckert & Zieglar, Bebig GmBH, Germany).

![Sagittal view of computed tomography scan of Plan 1 showing interrelationship of contoured volumes e.g. highrisk clinical target volume (HR-CTV) (brown), intermediate risk clinical target volume (IR-CTV) (orange), rectum (yellow), sigmoid colon (pink), bladder (blue), and urethra (violet)](JCB-8-28548-g001){#f0001}

In the subsequent fraction, with informed consent of the patient, we decided to go for interstitial brachytherapy (ISBT) implant. We inserted 10 metallic needles in two circles and the FSD tandem (previously used angulation) through Syed Neblett gynecological interstitial template on 09/09/2014. However, we failed to deliver the desired 7 Gy and prescribed only 5 Gy instead. For the prescription of 5 Gy, the dose levels were almost similar to the 1^st^ insertion: HR-CTV D~90~ (6.7 Gy), IR-CTV D~90~ (3.06 Gy), bladder D~2cc~ (5.7 Gy), rectum D~2cc~ (4.8 Gy), and sigmoid colon D~2cc~ (1.3 Gy). We could not deliver 7 Gy prescription due to high doses to the OAR in order to keep the EQD~2~ (equivalent dose in 2 Gy/fraction adding EBRT and brachytherapy doses, and considering α/β for OAR = 3 Gy and for tumor = 10 Gy) of bladder D~2cc~ \< 90 Gy, EQD~2~ rectum D~2cc~, and sigmoid colon D~2cc~ \< 70 Gy as mandated in our institutional protocol. Moreover, in order to get HR-CTV EQD~2~ of D~90~ \> 85 Gy, which is our institutional protocol, this prescription (if followed also in third fraction) would be suboptimal (Plan 2). On reviewing all the steps of the second fraction, we observed that the problem remained the same like the first fraction i.e. narrow space (average = 0.23 cm) between the rectum and the cervix.

Therefore, for the third fraction, with informed consent, we decided to instill hydrogel in the recto-vaginal space. On 12/09/2014 under spinal anesthesia, the patient underwent ISBT with Syed Neblett template (6 needles in inner circle of obturator and central FSD tandem). During this procedure, instillation of the hydrogel was also performed. After Foleys catheterization, a Cusco's self-retaining bivalve speculum was introduced, the os was identified, and a 50 cc syringe was filled with hydroxypropyl methylcellulose (Viscomet^®^). The needle of the syringe was inserted through the recto-vaginal septum. One index finger was kept per rectally to feel the passage of the needle of instilling syringe. Slowly, the hydrogel was instilled along the recto-vaginal septum. The needle was then carefully withdrawn while pushing the hydrogel as high as possible into the septum ([Figure 2](#f0002){ref-type="fig"}). After this, the ISBT insertion was done. The patient underwent a plain CT scan of pelvis with 2.5 mm slice thickness. The whole procedure was uneventful. We contoured the hydrogel area separately (Plan 3). We did a repeat CT scan with applicator in situ after the treatment was over (about 4 hours after hydrogel insertion) to find out any migration of hydrogel. We also contoured and planned virtually on this image dataset (Plan 4) and compared it dosimetrically with the third fraction insertion ([Figure 3](#f0003){ref-type="fig"}).

![Sagittal view of computed tomography scan of Plan 3 showing interrelationship of contoured volumes e.g. highrisk clinical target volume (HR-CTV) (brown), intermediate risk clinical target volume (IR-CTV) (orange), rectum (deep pink), sigmoid colon (light pink), bladder (light blue), urethra (violet), and Viscomet^®^ (deep blue)](JCB-8-28548-g002){#f0002}

![Sagittal view of computed tomography scan of Plan 4 showing interrelationship of contoured volumes e.g. highrisk clinical target volume (HR-CTV) (brown), intermediate risk clinical target volume (IR-CTV) (orange), rectum (deep pink), sigmoid colon (light pink), bladder (light blue), urethra (violet), and Viscomet^®^ (deep blue)](JCB-8-28548-g003){#f0003}

Results {#sec3}
=======

The instilled hydrogel area was optimally visible on planning CT between the anterior rectal wall and the posterior vaginal wall. The average width of separation was 1.1 cm, length of 5 cm. The patient was planned and we were able to deliver 9 Gy with an optimized dose distribution in the HR-CTV and OAR. Fraction-wise and total doses of CTV and OAR including the relative and absolute dosimetric changes from Plan 2 & Plan 3 are detailed in [Table 1](#t0001){ref-type="table"}. Dosimetric comparison of Plan 3 and Plan 4 are given in [Table 2](#t0002){ref-type="table"}. The hydrogel volume was decreased on Plan 4 with superior-inferior expansion (9.3 cc in Plan 3 \[supero-inferior × anterio-posterior × medio-lateral: being 4 × 1 × 2.5 cm, respectively\] versus 7.2 cc in Plan 4 \[5 × 0.8 × 2 cm respectively\]) without any major change in other dosimetric parameters.

###### 

Fraction wise and total dose distribution of all insertions

  Insertions                1^st^ insertion Plan 1   2^nd^ insertion Plan 2   3^rd^ insertion Plan 3   Absolute difference from Plan 3 --Plan 2 dose   Relative difference from Plan 3 --Plan 2 dose   EQD~2~ (EBRT + all BT)
  ------------------------- ------------------------ ------------------------ ------------------------ ----------------------------------------------- ----------------------------------------------- ------------------------
  Prescription dose         5 Gy                     5 Gy                     9 Gy                                                                     \%                                              
  All doses in Gy                                                                                                                                                                                      
  HR-CTV (α/β = 10)                                                                                                                                                                                    
   D~90~                    5.9                      6.7                      16.4                     9.7                                             48.2                                            98.4
   D~100~                   3.8                      4.5                      10.2                     5.7                                             23.3                                            72.1
   V~100~ (%)               96.3                     99.3                     100                      0.7                                                                                             98.5
  IRCTV (α/β = 10)                                                                                                                                                                                     
   D~90~                    4.5                      4.5                      11.3                     6.8                                             35.6                                            76.1
   D~100~                   2.7                      3.1                      4.1                      1.0                                             --16.4                                          56.2
   V~100~ (%)               85.5                     83.1                     95.7                     12.6                                                                                            88.1
  Bladder (α/β = 3)                                                                                                                                                                                    
   D~0.1cc~                 8.4                      5.7                      11.2                     5.5                                             10.4                                            106.3
   D~1cc~                   6.2                      4.1                      8                        3.9                                             6.9                                             80.2
   D~2cc~                   5.5                      3.6                      6.9                      3.3                                             4.7                                             73.2
  Rectum (α/β = 3)                                                                                                                                                                                     
   D~0.1cc~                 9.6                      11.0                     4.9                      --6.1                                           --156.6                                         108.1
   D~1cc~                   6.8                      6.2                      4                        --2.2                                           --79.6                                          75.7
   D~2cc~                   5.7                      4.8                      3.6                      --1.2                                           --56                                            67.7
  Sigmoid colon (α/β = 3)                                                                                                                                                                              
   D~0.1cc~                 9.6                      1.8                      3.1                      1.3                                             --1.6                                           75.1
   D~1cc~                   6.9                      1.4                      2.4                      1.3                                             --1.3                                           62.9
   D~2cc~                   5.9                      1.3                      2.2                      1.1                                             --1.6                                           59.3

EBRT -- external beam radiotherapy, BT -- brachytherapy, EQD~2~ -- equivalent dose in 2 Grey per fraction, HR-CTV -- high risk clinical target volume, D~90~ -- minimum dose received by 90% of the volume expressed as a percentage of the prescription dose, D~100~ -- minimum dose received by 100% of the volume expressed as a percentage of the prescription dose, V~100~ -- percentage of the target volume covered by 100% of the prescription dose, IR-CTV -- intermediate risk clinical target volume, D~0.1cc~ -- the minimum doses to the highest irradiated 0.1 cc volume, D~1cc~ -- the minimum doses to the highest irradiated 1 cc volume, D~2cc~ -- the minimum doses to the highest irradiated 2 cc volume

###### 

Comparative dosimetry of Plan 3 and Plan 4

  Insertions                                                 3^rd^ insertion Plan 3   Plan 4        Difference
  ---------------------------------------------------------- ------------------------ ------------- ------------
  Prescription dose                                          9 Gy                     9 Gy          
  HR-CTV (α/β = 10)                                                                                 
   D~90~                                                     16.4                     15.63         --0.77
   D~100~                                                    10.2                     10.36         0.15
   V~100~ (%)                                                100                      100           0
  IRCTV (α/β = 10)                                                                                  
   D~90~                                                     11.3                     9.12          --2.18
   D~100~                                                    4.1                      4.58          0.48
   V~100~ (%)                                                95.7                     90.6          --5.1
  Bladder (α/β = 3)                                                                                 
   D~0.1cc~                                                  11.2                     10.63         --0.57
   D~1cc~                                                    8                        8.17          0.17
   D~2cc~                                                    6.9                      7.06          0.66
  Rectum (α/β = 3)                                                                                  
   D~0.1cc~                                                  4.9                      5.16          0.26
   D~1cc~                                                    4                        4.19          0.19
   D~2cc~                                                    3.6                      3.71          0.11
  Sigmoid colon (α/β = 3)                                                                           
   D~0.1cc~                                                  3.1                      1.97          --1.13
   D~1cc~                                                    2.4                      1.63          --0.73
   D~2cc~                                                    2.2                      1.47          --0.73
  Hydrogel contour volume (cc)                               9.3                      7.2           --2.1
  Hydrogel volume dimension:                                                                        
   supero-inferior × antero-posterior × medio-lateral (cm)   4 × 1 × 2.5              5 × 0.8 × 2   

HR-CTV -- high risk clinical target volume, D~90~ -- minimum dose received by 90% of the volume expressed as a percentage of the prescription dose, D~100~ -- minimum dose received by 100% of the volume expressed as a percentage of the prescription dose, V~100~ -- percentage of the target volume covered by 100% of the prescription dose, IR-CTV -- intermediate risk clinical target volume, D~0.1cc~ -- the minimum doses to the highest irradiated 0.1 cc volume, D~1cc~ -- the minimum doses to the highest irradiated 1 cc volume, D~2cc~ -- the minimum doses to the highest irradiated 2 cc volume

Post implant days were uneventful. The patient was examined after 6 weeks. There was neither a residual tumor nor any adverse event. The patient remains in follow-up till date without any late toxicity and is in complete remission.

Discussion {#sec4}
==========

Most of the studies using hydrogel for rectal separation are in prostate cancer. In the first published report of this kind, Susil *et al*. showed that a decrease of rectal V~70~ Gy significantly from 23% baseline value to 15%, 4%, and 0% was possible with 5 mm, 10 mm, and 15 mm separation, respectively \[[@cit0010]\]. This finding was confirmed in further clinical studies \[[@cit0011], [@cit0012], [@cit0013], [@cit0014], [@cit0015], [@cit0016]\]. In their study, Prada *et al*. demonstrated that the measured rectal dose for HDR boost was significantly lower by about 2 Gy in prostate cancer patients \[[@cit0016]\]. Marnitz *et al*. demonstrated the use of recto-vaginal separation using hydrogel in EBRT for cervical cancer \[[@cit0012]\]. They achieved a median separation width of 10 mm, length of 32 mm.

To the best of our knowledge, our study is the first to report about rectal separation using hydrogel in brachytherapy for cervical cancer. We tried to increase the separation between the rectum and the cervical tissue in this difficult case where the septum width was very narrow (\< 1 cm: 0.23 cm). The idea was to deliver optimum dose to tumor target, keeping the rectal dose as low as possible. The average separation width achieved was 11 mm. The favorable dosimetric impact is depicted in [Table 1](#t0001){ref-type="table"}. We observed no adverse events during and after the procedure. The hydrogel volume was easily visible in CT scans with a slight migration, and the minor reduction noted in Plan 4 had no major impact on the dosimetric parameters.

Conclusions {#sec5}
===========

Hydrogel instillation may be a useful tool for recto-vaginal separation during brachytherapy of cervical cancer. It appears to increase the therapeutic ratio without any adverse event. Considering this to be the first report of its kind, we plan to prospectively try this approach in selected patients in the future.
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